2016
DOI: 10.1097/aog.0000000000001484
|View full text |Cite
|
Sign up to set email alerts
|

Committee Opinion No. 663

Abstract: Aromatase inhibitors have been used for the treatment of breast cancer, ovulation induction, endometriosis, and other estrogen-modulated conditions. For women with breast cancer, bone mineral density screening is recommended with long-term aromatase inhibitor use because of risk of osteoporosis due to estrogen deficiency. Based on long-term adverse effects and complication safety data, when compared with tamoxifen, aromatase inhibitors are associated with a reduced incidence of thrombosis, endometrial cancer, … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
5
0

Year Published

2016
2016
2020
2020

Publication Types

Select...
4
4

Relationship

0
8

Authors

Journals

citations
Cited by 21 publications
(5 citation statements)
references
References 40 publications
(31 reference statements)
0
5
0
Order By: Relevance
“…The most well-known AIs include anastrozole, letrozole, and fadrozole. They are mainly used in the treatment of gynecological cancers [ 100 ]. Their efficacy in UF treatments has also been confirmed [ 84 ] ( Figure 3 ).…”
Section: Discussionmentioning
confidence: 99%
“…The most well-known AIs include anastrozole, letrozole, and fadrozole. They are mainly used in the treatment of gynecological cancers [ 100 ]. Their efficacy in UF treatments has also been confirmed [ 84 ] ( Figure 3 ).…”
Section: Discussionmentioning
confidence: 99%
“…Nevertheless, studies that are more recent could not find an adverse effect on embryological, clinical or neonatal data for oocytes with smooth endoplasmic reticulum aggregates, since more than 20 children were born from oocytes with this abnormality. Moreover, the exclusion of these oocytes from ICSI cycles causes an increased frequency of transfer cancellation (Ashrafi et al, 2015;Shaw-Jackson et al, 2014;2016;Restelli et al, 2015).…”
Section: Discussionmentioning
confidence: 99%
“…Letrozole is an aromatase inhibitor (AI) developed in the 1990's, as an adjuvant in women with positive estrogen-receptor metastatic breast cancer, as it blocks catalytic conversion of androstenedione to estrone, and testosterone to estradiol ( Rodriguez-Wallberg & Oktay, 2010 ; Halászová et al ., 2017 ; Rodgers et al ., 2017 ). As a selective and reversible AI, it inhibits proliferation of estrogen-dependent breast cancer cells, promoting reduction of tumor recurrence and higher disease-free survival rates when administered as long-term adjuvant therapy ( Rodgers et al ., 2017 ; ACOG, 2016 ; Dahhan et al ., 2017 ; Taylan & Oktay, 2017 ).…”
Section: Introductionmentioning
confidence: 99%
“…The most well-known AIs are anastrozole, letrozole, and fadrozole. They are mainly used in the treatment of gynecological cancers (breast or endometrial cancer) [ 104 ], to suppress estrogen production [ 104 ], and to treat endometriosis [ 105 , 106 , 107 ] or infertility (induction of the ovulation) [ 107 ]. AIs have good efficacy, but they can cause common side effects, such hot flashes, bone loss, mood swings, vaginal dryness, ovarian cyst formation, or body pain [ 108 ].…”
Section: Discussionmentioning
confidence: 99%